ESR1 and breast cancer: Pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) reduces the expression of leptin receptor and VEGFR2 in tumor cells, which inhibits the proliferation, angiogenesis and metastasis of ER+ and ER- BC [163].